Finance

Lists
Outlook: 40.0% bullish·0.0% bearish
Go to analysis
M1CK34:BVMF
Mckesson Corp Bdr
73,22 BRL
0,00%
(0,00) 1D
9-окт., 16:37:40 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for M1CK34...
Open
72,80 BRL
High
73,43 BRL
Low
72,80 BRL
Mkt. cap
109,45 млд
Avg. vol.
296,00
Volume
69,00
52-wk high
81,67 BRL
52-wk low
55,63 BRL
Shares outstanding
116,59 млн
No. of employees
42 миң
Open
72,80 BRL
High
73,43 BRL
Low
72,80 BRL
Mkt. cap
109,45 млд
Avg. vol.
296,00
Volume
69,00
52-wk high
81,67 BRL
52-wk low
55,63 BRL
Shares outstanding
116,59 млн
No. of employees
42 миң
News stories
From web sources and news partners
Profile
McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. With $308.9 billion in 2024 revenue, it is the ninth-largest company by revenue in the United States and the nation's largest health care company. The company is headquartered in Irving, Texas. It is a component of the S&P 500 and is listed on the New York Stock Exchange, where it is traded under the ticker symbol "MCK". McKesson provides extensive network of infrastructure for the healthcare industry and was an early adopter of technologies, including barcode scanning for distribution, pharmacy robotics, and RFID tags. The company has been named in a federal lawsuit for profiting from the opioid epidemic in the United States. Throughout the COVID-19 pandemic, McKesson was a key vaccine distributor, serving as the US government's centralized distributor for hundreds of millions of COVID-19 vaccine doses and ancillary supply kits for over a billion doses. Wikipedia
About Mckesson Corp Bdr
CEOBrian S. Tyler
Employees42,3 миң
Founded1835
Headquarters-
SectorHealth care provider
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
103,15 млд
106,16 млд
96,30 млд
105,38 млд
Cost of goods sold
99,61 млд
102,49 млд
92,25 млд
101,70 млд
Cost of revenue
99,61 млд
102,49 млд
92,25 млд
101,70 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,12 млд
2,03 млд
1,92 млд
2,26 млд
Operating expense
2,12 млд
2,03 млд
1,92 млд
2,26 млд
Total operating expenses
101,73 млд
104,52 млд
94,17 млд
103,96 млд
Operating income
1,42 млд
1,64 млд
2,13 млд
1,42 млд
Other non operating income
62,00 млн
74,00 млн
-156,00 млн
66,00 млн
EBT including unusual items
1,40 млд
1,63 млд
2,12 млд
1,31 млд
EBT excluding unusual items
1,40 млд
1,65 млд
2,10 млд
1,41 млд
Income tax expense
232,00 млн
380,00 млн
270,00 млн
276,00 млн
Effective tax rate
16,63%
23,31%
12,71%
21,10%
Other operating expenses
-
-
-
-
Net income
1,11 млд
1,19 млд
1,68 млд
614,00 млн
Net profit margin
1,08%
1,12%
1,75%
0,58%
Earnings per share
9,86
9,34
11,69
9,93
Interest and investment income
-
-
179,00 млн
-
Interest expense
-74,00 млн
-63,00 млн
-61,00 млн
-77,00 млн
Net interest expenses
-74,00 млн
-63,00 млн
118,00 млн
-77,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,60 млд
1,83 млд
2,19 млд
1,62 млд
Gain or loss from assets sale
-102,00 млн
-
-488,00 млн
-6,00 млн
AI content may include mistakes. Learn more
Google колдонмолору